Dr. Farshid Dayyani
Claim this profileUC Irvine Health/Chao Family Comprehensive Cancer Center
Expert in Adenocarcinoma
Studies Cancer
21 reported clinical trials
48 drugs studied
About Farshid Dayyani
Education:
- Earned an MD from Ludwig Maximilian University of Munich, Germany (Class of 2002).
- Completed Residency in Internal Medicine at Beth Israel Deaconess Medical Center (2006-2008).
- Undertook a Fellowship in Hematology and Medical Oncology at the University of Texas Health Science Center at Houston/MD Anderson Cancer Center (2008-2011).
Experience:
- Serves as Associate Director for Translational Science at UC Irvine Health/Chao Family Comprehensive Cancer Center.
- Holds the position of Medical Director for the Stern Center for Cancer Clinical Trials & Research.
- Appointed Chief of the Division of Hematology/Oncology at UC Irvine School of Medicine.
- Actively involved in clinical trials as Principal Investigator.
Area of expertise
1Adenocarcinoma
Global LeaderStage IV
Stage III
HER2 positive
2Cancer
Stage IV
Stage III
HER2 positive
Affiliated Hospitals
Clinical Trials Farshid Dayyani is currently running
ctDNA-Guided Therapy
for Colorectal Cancer
This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.
Recruiting1 award Phase 1
Disitamab Vedotin + Tucatinib
for Breast Cancer
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV, with or without tucatinib, is for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Recruiting1 award Phase 1 & 26 criteria
More about Farshid Dayyani
Clinical Trial Related4 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Farshid Dayyani has experience with
- Nivolumab
- Irinotecan
- Paclitaxel
- Docetaxel
- TAS-102
- Pembrolizumab
Breakdown of trials Farshid Dayyani has run
Adenocarcinoma
Cancer
Tumors
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Farshid Dayyani specialize in?
Farshid Dayyani focuses on Adenocarcinoma and Cancer. In particular, much of their work with Adenocarcinoma has involved Stage IV patients, or patients who are Stage III.
Is Farshid Dayyani currently recruiting for clinical trials?
Yes, Farshid Dayyani is currently recruiting for 7 clinical trials in Orange California. If you're interested in participating, you should apply.
Are there any treatments that Farshid Dayyani has studied deeply?
Yes, Farshid Dayyani has studied treatments such as Nivolumab, Irinotecan, Paclitaxel.
What is the best way to schedule an appointment with Farshid Dayyani?
Apply for one of the trials that Farshid Dayyani is conducting.
What is the office address of Farshid Dayyani?
The office of Farshid Dayyani is located at: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California 92868 United States. This is the address for their practice at the UC Irvine Health/Chao Family Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.